MCVEF Medicover AB Forecast, Technical & Fundamental Analysis

MCVEF's Stochastic Oscillator ascends into overbought zone

The Stochastic Oscillator for MCVEF moved into overbought territory on September 05, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Technical Analysis (Indicators)

Bearish Trend Analysis

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MCVEF just turned positive on September 03, 2025. Looking at past instances where MCVEF's MACD turned positive, the stock continued to rise in of 10 cases over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MCVEF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.547) is normal, around the industry mean (8.660). P/E Ratio (81.150) is within average values for comparable stocks, (116.721). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.012). Dividend Yield (0.006) settles around the average of (0.039) among similar stocks. P/S Ratio (1.558) is also within normal values, averaging (1.547).